Absence of Developmental Effects in CF-1 Mice Exposed to Aspartame in Utero

Aspartame (L-aspartyl-L-phenylalanine methyl ester) is a widelyused high potency dipeptide sweetener. Developmental toxicologystudies have been performed in several species documenting noeffects of high doses of aspartame. Recently, a study by Mahalikand Gautieri ((1984) Res Commun. Psychol Psychiatry Behav. 9,385–403) reported a delay in the achievement age for thevisual placing response in mice pups after maternal administrationof high dosages of aspartame during late gestation. In the presentstudy developmental parameters were determined in offspringof CF-1 mice after maternal administration of aspartame at 500,1000, 2000, and 4000 mg/kg body wt by oral gavage. Aspartamewas administered on Days 15 through 18 of gestation. Maternalbody weight, food consumption, gestation length, reproductiveindices, and litter size were not affected by aspartame treatment.In the pups, body weights, negative geotaxis, and surface andmidair righting reflexes were not altered by treatment. Therewas no delay in the development of the visual placing responseregardless of the method employed for assessment (grid or rope)or the manner by which the data were analyzed. There were alsono changes in time of eye opening, reflex pupil closure, andophthalmoscopic examination in the offspring. Thus, neitherphysical nor functional development was altered in mice afterin utero exposure to extremely large dosages of aspartame. Morespecifically, in utero exposure to aspartame did not affectthe development of the visual system in mice.     

Panniculitis in childhood and adolescence

Background: The purpose of the present paper was to describe the clinical manifestations and treatment of patients with panniculitis. Methods: From January 1983 to December 2002, 4294 patients were treated for pediatric rheumatological diseases at Pediatric Rheumatology Unit, University of São Paulo, Brazil. Of these, 35 children and adolescents (0.8%) presented with panniculitis: erythema nodosum (EN) or Weber–Christian disease (WCD). Clinical characteristics, laboratory exams, biopsy of the lesion, treatment and clinical course were studied. Results: Of the 35 patients, 29 presented with EN and six with WCD, one of these with cytophagic histiocytic panniculitis. Mean age at symptom onset was 85 months (6–204 months) and the mean duration of follow up was 55 months (1–144 months). All the patients presented with inflammatory subcutaneous nodules. The patients with WCD presented with systemic manifestations and cutaneous atrophy. The principal etiologies of EN were streptococcal infection (42%), undetermined (13.5%), pulmonary tuberculosis (10%), and acute rheumatic fever (10%). Biopsy of the nodules indicated septal panniculitis in 14 patients with EN and lobular panniculitis without vasculitis in the patients with WCD, one of which had cytophagic histiocytic panniculitis. There was recurrence in 11 patients (38%) with EN and in all those with WCD. Non‐steroidal anti‐inflammatory drugs were used in 15 patients with EN and corticosteroids and/or immunosuppressive drugs in the six patients with WCD. Three patients died. Conclusions: EN is the most frequent panniculitis, with a benign course and is mainly associated with infections. WCD is a severe disease, with systemic involvement, that proceeds with cutaneous atrophy and requires the use of corticosteroids and or immunosuppressive drugs.